Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroendocrine Tumor and Neurodegenerative Disease Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Synaptophysin (SYP) drug discovery and diagnostic development. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Synaptophysin (SYP) Extracellular Loop 2 (EC2) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View SYP Products |
| Gene Delivery | Synaptophysin (SYP) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to preserve native conformation. |
View SYP Products |
| Benchmark Ab | Anti-Synaptophysin (SYP) Recombinant Antibody Recombinant positive control for IHC, Western Blot, and flow cytometry. |
View SYP Products |
| Validator | Synaptophysin (SYP) siRNA Set For knockdown verification in target-specificity assays. |
View SYP Products |
| Related Target A | Chromogranin A (CHGA) Synergistic neuroendocrine biomarker used in combination panels for tumor profiling. |
View CHGA Products |
| Related Target B | Synaptic Vesicle Glycoprotein 2A (SV2A) Parallel synaptic vesicle target critical for neuropsychiatric and PET imaging assays. |
View SV2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane conformation preservation | Lentivirus-driven stable cell line expression to present native 4-transmembrane structure. |
| Epitope specificity (vs Synaptogyrin) | Sequence-verified Extracellular Loop 2 (EC2) proteins for precise antibody counter-screening. |
| Lack of Controls | Recombinant positive control antibodies (Biosimilars) available. |
| False Positives | Validated siRNA included for specificity checks. |
Live Synaptophysin (SYP) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical utility of Synaptophysin (SYP) is expanding rapidly beyond its classic role as a gold-standard diagnostic biomarker for neuroendocrine tumors (NETs) and small cell lung cancer (SCLC). As therapeutic modalities evolve, SYP is increasingly investigated as a target for antibody-drug conjugates (ADCs), radioligand therapies, and as a key quantitative biomarker for synaptic density in neurodegenerative conditions such as Alzheimer's disease.
The next wave of R&D focuses on high-affinity recombinant antibodies capable of differentiating tumor-specific glycosylation patterns of SYP, as well as ultra-sensitive assays to monitor synaptic loss in central nervous system (CNS) disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Academic Medical Centers, Biotech Startups | Neuroendocrine Tumors (NETs), SCLC | Internalization Assay (Need high-purity, native-conformation stable cell lines) |
| Diagnostic Immunohistochemistry (IHC) | Roche (Ventana), Agilent (Dako), Leica Biosystems | Neuroendocrine Cancers, Gliomas | High-specificity recombinant proteins for epitope mapping and counter-screening |
| Neuroscience Biomarker Assays | Pharmaceutical R&D Divisions, CROs | Alzheimer's, Schizophrenia | Quantitative ELISA development using sequence-verified, endotoxin-controlled antigens |